Silexion Therapeutics (SLXN) Total Non-Current Liabilities (2023 - 2026)
Silexion Therapeutics (SLXN) posted quarterly Total Non-Current Liabilities of $251000.0 for Q1 2026, down 92.46% year-over-year from $3.3 million in Q1 2025, and down 86.46% quarter-over-quarter from $1.9 million in Q4 2025.
Silexion Therapeutics (SLXN) Total Non-Current Liabilities (2023 - 2026) Analysis & Trends
Silexion Therapeutics' Total Non-Current Liabilities history runs 4 years deep, the most recent figure standing at $251000.0 for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 92.46% year-over-year to $251000.0; the TTM figure through Mar 2026 stood at $251000.0 (down 92.46% YoY), while the FY2025 annual figure was $1.9 million, down 44.31% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $251000.0, down from $1.9 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $4.1 million in Q3 2024, with the low at $8000.0 in Q2 2024.
- The 4-year median for Total Non-Current Liabilities is $1.9 million (2025), against an average of $2.0 million.
- The sharpest annual moves came in 2025 and 2026: Total Non-Current Liabilities soared 43987.5% in 2025, then sank 92.46% in 2026.
- Silexion Therapeutics' Total Non-Current Liabilities stood at $59000.0 in 2023, then soared by 5542.37% to $3.3 million in 2024, then tumbled by 44.31% to $1.9 million in 2025, then tumbled by 86.46% to $251000.0 in 2026.
- Business Quant data shows SLXN's Total Non-Current Liabilities at $251000.0 in Q1 2026, $1.9 million in Q4 2025, and $1.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Silexion Therapeutics | 266,692.97 | -1.96 Mn | - | 226,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 226,000.00 |
| Mar 31, 2026 | 251,000.00 |
| Dec 31, 2025 | 1.85 Mn |
| Sep 30, 2025 | 1.85 Mn |
| Jun 30, 2025 | 3.53 Mn |
| Mar 31, 2025 | 3.33 Mn |
| Dec 31, 2024 | 3.33 Mn |
| Sep 30, 2024 | 4.08 Mn |
| Jun 30, 2024 | 8,000.00 |
| Dec 31, 2023 | 59,000.00 |